Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer : New Environmental and Molecular Mutagenesis Study Findings Have Been Reported by Researchers at Bayer (Classification of in vitro genotoxicants using...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:27pm CET

New Environmental and Molecular Mutagenesis Study Findings Have Been Reported by Researchers at Bayer (Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test)

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators publish new report on Environmental and Molecular Mutagenesis. According to news originating from Berlin, Germany, by NewsRx correspondents, research stated, "Regulatory in vitro genotoxicity testing exhibits shortcomings in specificity and mode of action (MoA) information. Thus, the aim of this work was to evaluate the performance of the novel MultiFlow assay composed of mechanistic biomarkers quantified in TK6 cells after treatment (4 and 24 hr): gH2AX (DNA double strand breaks), phosphorylated H3 (mitotic cells), translocated p53 (genotoxicity), and cleaved PARP1 (apoptosis)."

Our news journalists obtained a quote from the research from Bayer, "A reference dataset of 31 compounds with well-established MoA was studied using the MicroFlow micronucleus assay. A positive call was raised following the earlier published criteria from Litron Laboratories. In the light of our data, these evaluation criteria should probably be adjusted since only 8/11 (73%) nongenotoxicants and 18/20 (90%) genotoxicants were correctly identified. Moreover, there is a need for new in vitro tools to delineate the predominant MoA as in the MicroFlow assay only 5/9 (56%) aneugens and 4/11 (36%) clastogens were correctly classified. In contrast, the MultiFlow assay provides more in-depth information about the MoA and therefore reliably discriminates clastogens, aneugens, and nongenotoxicants. By using a lab-specific, practical threshold for the aforementioned biomarkers, 10/11 (91%) nongenotoxicants and 19/20 genotoxicants (95%), 9/11 (82%) clastogens, and 8/9 (89%) aneugens were correctly categorized, suggesting a clear improvement over the MicroFlow. Furthermore, the MultiFlow markers were benchmarked against established methods to assess the validity of the data. Altogether, these findings demonstrated good agreement between the MultiFlow assay and the benchmarking methods."

According to the news editors, the research concluded: "Finally, p21 may improve class discrimination given the correct identification of 4/4 (100%) aneugens and 2/5 (40%) clastogens."

For more information on this research see: Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test. Environmental and Molecular Mutagenesis, 2017;():. (Wiley-Blackwell - www.wiley.com/; Environmental and Molecular Mutagenesis - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1098-2280)

The news correspondents report that additional information may be obtained from S. Wilde, Investigational Toxicology, Bayer AG, Berlin, Germany. Additional authors for this research include M. Dambowsky, C. Hempt, A. Sutter and N. Queisser (see also Environmental and Molecular Mutagenesis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/em.22130. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Berlin, Europe, Germany, Genetics, Environmental and Molecular Mutagenesis.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
01/11 Bayer raises higher than expected 1.8 billion euros from Covestro placement
01/11 BAYER : Reduces Direct Stake in Covestro to 14.2%
01/11 BAYER : sells 10.4 percent stake in Covestro
01/10 Bayer to sell Covestro shares worth about $1.8 billion
01/10 BAYER : Further Reduces Stake in Covestro
01/10 BAYER : further reduces holding in Covestro
01/10 Bayer, J&J win reversal of US$28 million verdict in Xarelto lawsuit
01/10 BAYER : and Round Table on Responsible Soy renew cooperation
01/10 BAYER : J&J win reversal of $28 million verdict in Xarelto lawsuit
01/08 BAYER : inaugurates new greenhouse for insecticide research
More news
News from SeekingAlpha
01:11p Greenlight Capital's (David Einhorn) Q4 2017 Letter
01/15 ROAD TO FINANCIAL INDEPENDENCE : My December 88-Stock Portfolio Review
01/11 Bayer sells 10.4% stake in Covestro, raising ?1.8B
01/07 Rethinking Free Cash Flow
2017 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 26, 2017
Financials (€)
Sales 2017 36 021 M
EBIT 2017 7 716 M
Net income 2017 6 565 M
Debt 2017 8 839 M
Yield 2017 2,51%
P/E ratio 2017 13,58
P/E ratio 2018 18,26
EV / Sales 2017 2,64x
EV / Sales 2018 2,43x
Capitalization 86 416 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 122 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER0.48%106 071
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987